New directions in the treatment of anxiety disorders

Bibliography

• HEIMBERG RG, LIEBOWITZ MR, HOPE DA et al.: Cognitive behavioral group therapy versus phenelzine therapy for social phobia: 12-week outcome. Arch. Gen. Psychiatry (1998) 55(12):1133–1141.
   PubMed Web of Science ®Google Scholar
• LIEBOWITZ MR, HEIMBERG RG, SCHNEIER FR et a/.: Cognitive-behavioralgroup therapy versus phenelzine in social phobia: long-term outcome. Depression &-Anxiety (1999) 10:89–98.
   Google Scholar
• HOOD SD, NUTT DJ: How I treat St John's Wort. The Practitioner (1999) 243:779–786.
   PubMedGoogle Scholar
• HOOD SD, ALDERTON D, CASTLE DJ: OCD: treatment and treatment resistance. Australasian Psychiatry (2001) 19:118–127.
   Google Scholar
• PAMPALLONA S, BOLLINI P, TIBALDI G, KUPELNICK B, MUNIZZA C: Patient adherence in the treatment of depression. Br. Psychiatry (2002) 180:104–109.
   PubMed Web of Science ®Google Scholar
• BALLENGER JC, DAVIDSON JRT, LECRUBIER Y et al: Consensus statement on panic disorder from the international consensus group on depression and anxiety. Clin. Psy. (1998) 59\(Supp1.8):47–54.
   Google Scholar
• CROWE RR, NOYES R, PAULS DL, SLYMEN D: A family study of panic disorder. Arch. Gen. Psychiatry (1983) 40(10):1065–1069.
   PubMed Web of Science ®Google Scholar
• MAIER W, LICHTERMANN D, MINGES J, OEHRLEIN A, FRANKE P: A controlled family study in panic disorder. Psychiatc Res. (1993) 27\(Supp1.1):79–87.
   Google Scholar
• KENDLER KS, NEALE MC, KESSLER RC, HEATH AC, EAVES LJ: Panic disorder in women: a population-based twin study. Psycho]. Med. (1993) 23(2):397–406.
   PubMed Web of Science ®Google Scholar
• PERNA G, CALDIROLA D, ARANCIO C, BELLODI L: Panic attacks: a twin study. Psychiatry Res. (1997) 66(1):69–71.
   PubMed Web of Science ®Google Scholar
• MARTINSANTOS R, BULBENA A, PORTA M, GAGO J, MOLINA L, DURO JC: Association between joint hypermobility syndrome and panic disorder. Am. J. Psychiatry (1998) 155(11):1578–1583.
   PubMedGoogle Scholar
• GRATACOS M, NADAL M, MARTIN-SANTOS R et al.: A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell (2001) 106(3):367–379.
   PubMedGoogle Scholar
• WEISSMAN MM, GROSS R, FYER A et al.: Interstitial cystitis and panic disorder: a potential genetic syndrome. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) HT19.
   Google Scholar
• KLEIN DF: False suffocation alarms, spontaneous panics, and related conditions. an integrative hypothesis. Arch. Gen. Psychiatry (1993) 50(4):306–17.
   PubMed Web of Science ®Google Scholar
• PERNA G, BERTANI A, CALDIROLA D, GABRIELE A, COCCHI S, BELLODI L: Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. Clin. Psychopharmacol (2002) 22(3):300–308.
   PubMed Web of Science ®Google Scholar
• BRANNAN S, LIOTTI M, EGAN G et al: Neuroimaging of cerebral activations and deactivations associated with hypercapnia and hunger for air. Proc. Natl. Acad. Sci. USA(2001) 98(02029–2034.
   PubMed Web of Science ®Google Scholar
• ARGYROPOULOS SV, BAILEY JE, HOOD SD et al.: Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology(2002) 27:715–729.
   PubMed Web of Science ®Google Scholar
• SASAKI I, AKIYOSHI J, SAKURAI R et a/.: Carbon dioxide induced panic attack in panic disorder in Japan. Frog. Neuropsychopharmacol Biol. Psychiatry (1996) 20(7):1145–57.
   Google Scholar
• SINHA SS, COPLAN JD, PINE DS, MARTINEZ JA, KLEIN DF, GORMAN JM: Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res. (1999) 86(2):93–98.
   PubMedGoogle Scholar
• COPLAN JD, MOREAU D, CHAPUT F et al.: Salivary cortisol concentrations before and after carbon-dioxide inhalations in children. Biol. Psychiatry(2002)51(4):326–333.
   PubMedGoogle Scholar
• COPLAN JD, MOREAU D, CHAPUT F et al.: Salivary cortisol concentrations before and after carbon-dioxide inhalations in children. Biol. Psychiatry(2002)51(4):326–333.
   PubMedGoogle Scholar
• KAYE J, LIGHTMAN S: Monoaminergic systems regulating neuroendocrine, autonomic and behavioural responses to acute hypercapnia. Fifth International Congress of Neuroendocrtinology Bristol (2002).
   Google Scholar
• KAYE J, BUCHANAN F, KENDRICK A, LIGHTMAN S: Endocrine, behavioural and physiological responses to acute hypercapnia. A novel means of investigating stress responsivity. The 84th Annual Meeting of the Endocrine Society San Francisco (2002).
   Google Scholar
• GORMAN JM, LIEBOWITZ MR, FYER AJ, STEIN J: A neuroanatomical hypothesis for panic disorder. Am. Psychiatry (1989) 146(2):148–161.
   PubMed Web of Science ®Google Scholar
• •Although now slightly dated and recently revised, this heuristic paper guided anxiety disorder research in the 1990s.
   Google Scholar
• GORMAN JM, KENT JM, SULLIVAN GM, COPLAN JD: Neuroanatomical hypothesis of panic disorder, revised. Am. I Psychiatry (2000) 157(4):493–505.
   PubMed Web of Science ®Google Scholar
• BAKKER A, VAN BALKOM AJ, SPINHOVEN P: SSRIs versus TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr. Scand. (2002) 106(3):163–167.
   PubMed Web of Science ®Google Scholar
• DANNON PN, IANCU I, GRUNHAUS L: The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum. Psychopharmacol (2002) 17(7):329–333.
   PubMed Web of Science ®Google Scholar
• VALENCA AM, NARDI AE, NASCIMENTO I, MEZZASALMA MA, LOPES FL, ZIN W: Double-blind clonazepam versus placebo in panic disorder treatment. Arq. Neuropsiquiad. (2000) 58(4):1025–1029.
   PubMed Web of Science ®Google Scholar
• GODDARD AW, BROUETTE T, ALMAI A, JETTY P, WOODS SW, CHARNEY D: Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry(2001) 58(7):681–686.
   PubMed Web of Science ®Google Scholar
• GARCIA-TORO M, SALVA CJ, CRESPI FM, ANDRES TJ, AGUIRRE OI, BOSCH CC: Panic disorder and transcranial magnetic stimulation. Actor Esp. Psiquiatr. (2002) 30(4):221–224.
   PubMedGoogle Scholar
• HAZLETT-STEVENS H, CRASKE M, ROY-BYRNE P, SHERBOURNE C, STEIN M, BYSTRITSKY A: Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients. Gen. Hosp. Psychiatry (2002) 24(5):316.
   PubMedGoogle Scholar
• ISSAKIDIS C, ANDREWS G: Service utilisation for anxiety in an Australian community sample. Soc. Psychiatry Psychiam Epidemiol (2002) 37(4):153–163.
   PubMedGoogle Scholar
• KAMPMAN M, KEIJSERS GP, HOOGDUIN CA, HENDRIKS GJ: A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. j. Clin. 1Tchiauy(2002) 63(9):772–777.
   Google Scholar
• ARNTZ A: Cognitive therapy versus interoceptive exposure as treatment of panic disorder without agoraphobia. Behav. Res. Ther. (2002) 40(3):325–341.
   PubMedGoogle Scholar
• OTTO MW, HONG JJ, SAFREN SA: Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behaviour therapy. Curt-. Pharm. Des. (2002) 8(1):75–80.
   PubMedGoogle Scholar
• WESTRA HA, STEWART SH, CONRAD BE: Naturalistic manner of benzodiazepine use and cognitive behavioural therapy outcome in panic disorder with agoraphobia. J. Anxiety Disord. (2002) 16(3):233–246.
   PubMedGoogle Scholar
• GODDARD AW, BROUETTE T, ALMAI A, JETTY P, WOODS SW, CHARNEY D: Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry (2001) 58(7):681–686.
   PubMed Web of Science ®Google Scholar
• DUGAS MJ: Generalized anxiety disorder publications: so where do we stand? j Anxiety Disord. (2000) 14(1):31–40.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders. (Third Edition), American Psychiatric Association, Washington DC, USA (1980).
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders. (Fourth Edition), American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• KESSLER RC, WITTCHEN HU: Patterns and correlates of generalized anxiety disorder in community samples. I Clin. Psychiatry (2002) 8(63 Suppl.):4–10.
   Google Scholar
• HUNT C, ISSAKIDIS C, ANDREWS G: DSM-IV generalized anxiety disorder in the Australian national survey of mental health and well-being. Psycho]. Med. (2002) 32(4):649–659.
   PubMed Web of Science ®Google Scholar
• TURNER SM, BEIDEL DC, STANLEY MA: Are obsessional thoughts and worry different cognitive phenomena? Chu. Psychology Rev. (1992) 12:257–270.
   Google Scholar
• LANGLOIS F, FREESTON MH, LADOUCEUR R Differences and similarities between obsessive intrusive thoughts and worry in a non-clinical population: study 1. Behav. Res. Ther. (2000) 38(2):157–173.
   PubMedGoogle Scholar
• LANGLOIS F, FREESTON MH, LADOUCEUR R: Differences and similarities between obsessive intrusive thoughts and worry in a non-clinical population: study 2. Behav. Res. The]: (2000) 38(2):175–189.
   PubMedGoogle Scholar
• BREITHOLTZ E, JOHANSSON B, OST LG: Cognitions in generalized anxiety disorder and panic disorder patients. a prospective approach. Behav. Res. Ther.(1999) 37(6):533–544.
   PubMed Web of Science ®Google Scholar
• HAMILTON M: The assessment of anxietystates by rating. Br: J. Med. Psycho]. (1959) 32:50–55.
   PubMed Web of Science ®Google Scholar
• CULPEPPER L: Generalized anxiety disorder in primary care: emerging issues in management and treatment. J. Clin. Psychiatry (2002) 8(63 Suppl.):35–42.
   Google Scholar
• GORMAN JM: Treatment of generalized anxiety disorder. J. Chu. Psychiatry (2002) 8(63 Suppl.):17–23.
   Google Scholar
• KATZ IR, REYNOLDS CF III, ALEXOPOULOS GS, HACKETT D: Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J. Am. Geriatt: Soc. (2002) 50(1):18–25.
   PubMedGoogle Scholar
• SRAMEK JJ, ZAROTSKY V, CUTLER NR: Generalised anxiety disorder: treatment options. Drugs (2002) 62(11):1635–1648.
   PubMed Web of Science ®Google Scholar
• BORKOVEC TD, NEWMAN MG, PINCUS AL, LYTLE R: A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J. Consult. Chu. Psycho]. (2002) 70(2):288–298.
   PubMed Web of Science ®Google Scholar
• CONNOR KM, DAVIDSON JR: A placebo-controlled study of Kava kava in generalized anxiety disorder. Int. Chu. Psychopharmacol (2002) 17(4):185–188.
   PubMedGoogle Scholar
• KESSLER RC, SONNEGA A, BROMET E, HUGHES M, NELSON CB: Posttraumatic stress disorder in the national comorbidity survey. Arch. Gen. Psychiatry(1995) 52(12):1048–1060.
   PubMed Web of Science ®Google Scholar
• BRE WIN CR, ANDREWS B, VALENTINE JD: Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. Consult. Gin. Psycho]. (2000) 68(5):748–766.
   PubMedGoogle Scholar
• MAYOU RA, EHLERS A, HOBBS M: Psychological debriefing for road traffic accident victims. Three-year follow-up of a randomised controlled trial. Br. I Psychiatry (2000) 176:589–593.
   Google Scholar
• SHAPIRO F: Eye movement desensitization and reprocessing (EMDR) and the anxiety disorders: clinical and research implications of an integrated psychotherapy treatment. Anxiety Disord. (1999) 13(1-2):35–67.
   PubMed Web of Science ®Google Scholar
• YEHUDA R: Current status of cortisol findings in post-traumatic stress disorder. Psychiatc Clin. North Am. (2002) 25(2):341–368,vii.
   Google Scholar
• BREMNER JD, RANDALL P, SCOTT TMet al.: MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am. J. Psychiatry (1995) 152(7):973–981.
   Google Scholar
• MARSHALL RD, BEEBE KL, OLDHAM M, ZANINELLI R: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry (2001) 158(12):1982–1988.
   PubMed Web of Science ®Google Scholar
• DAVIDSON J, PEARLSTEIN T, LONDBORG P et al.: Efficacy of sertraline in preventing relapse of post-traumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am. J. Psychiatry (2001) 158 (12):1974–1981.
   PubMed Web of Science ®Google Scholar
• TUCKER P, ZANINELLI R, YEHUDA R, RUGGIERO L, DILLINGHAM K, PITTS CD: Paroxetine in the treatment of chronic post-traumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry (2001) 62(11):860–868.
   PubMed Web of Science ®Google Scholar
• RAPAPORT MH, ENDICOTT J, CLARY CM: Post-traumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. I. Clin. Psychiatry (2002) 63(1):59–65.
   PubMedGoogle Scholar
• CONNOR KM, SUTHERLAND SM, TUPLER LA, MALIK ML, DAVIDSON JR: Fluoxetine in post-traumatic stress disorder. randomised, double-blind study. Br. j Psychiatry (1999) 175:17–22.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR: Pharmacotherapy of post-traumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. Clin Psychiatry(2000) 61\(Supp1.5):52–56.
   Google Scholar
• BRADY KT, BACK SE: PTSD, gender, and pharmacotherapy. In: Gender and PTSD. Guilford Press, New York, USA 335–345.
   Google Scholar
• BUTTERFIELD MI, BECKER M, MARX CE: Post-traumatic stress disorder in women: current concepts and treatments. Cur. Psychiatry Reports (2002) 4:474–486.
   PubMedGoogle Scholar
• HAGEMAN I, ANDERSEN HS, JORGENSEN MB: Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiam Scand. (2001) 104(6):411–422.
   PubMedGoogle Scholar
• HAGEMAN I, ANDERSEN HS, JORGENSEN MB: Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiam Scand. (2001) 104(6):411–422.
   PubMedGoogle Scholar
• MAYOU RA, BLACK J, BRYANT B: Unconsciousness, amnesia and psychiatric symptoms following road traffic accident injury. Br: J. Psychiatry (2000) 177:540–545.
   PubMed Web of Science ®Google Scholar
• MURRAY J, EHLERS A, MAYOU RA: Dissociation and post-traumatic stress disorder: two prospective studies of road traffic accident survivors. Br. J. Psychiatry (2002) 180:363–368.
   PubMed Web of Science ®Google Scholar
• SHAPIRO DA, ROTH BL: Insights into the structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development. Expert Opin. Ther. Targets (2001) 5(6):685–695.
   PubMedGoogle Scholar
• HANNON J, HOYER D: Serotonin receptors and systems: endless diversity? Acta Biologica Szegediensis (2002) 46:1–12.
   Google Scholar
• BAUMGARTEN HG, GROZDANOVIC Z: Role of serotonin in obsessive-compulsive disorder. Br. Psychiatry (1998) 35 (Suppl.):13–20.
   Google Scholar
• GREIST JH, JEFFERSON JW, KOBAK KA, KATZELNICK DJ, SERLIN RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch. Gen. Psychiatry(1995) 52(1):53–60.
   PubMed Web of Science ®Google Scholar
• PICCINELLI M, PINI S, BELLANTUONO C, WILKINSON G: Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br. I Psychiatry(1995) 166(4):424–443.
   PubMed Web of Science ®Google Scholar
• STEIN DJ, SPADACCINI E, HOLLANDER E: Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int. Clin. Psychopharmacol (1995) 10(1):11–18.
   PubMed Web of Science ®Google Scholar
• LOPEZ-IBOR JJJ, SAIZ J, COTTRAUX J et al.: Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur: Neuropsychopharmacol (1996) 6(2):111–118.
   PubMedGoogle Scholar
• MUNDO E, MAINA G, USLENGHI C: Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol (2000) 15(2):69–76.
   PubMed Web of Science ®Google Scholar
• KORAN LM, MCELROY SL, DAVIDSON JR, RASMUSSEN SA, HOLLANDER E, JENIKE MA: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. I Clin. Psychopharmacol (1996) 16(2):121–129.
   Google Scholar
• ZOHAR J, JUDGE R: Paroxetine versus clomipramine in the treatment of obsessive- compulsive disorder. OCD paroxetine study investigators. Br. J. Psychiatry (1996) 169(4):468–474.
   PubMed Web of Science ®Google Scholar
• WADE D: Perfect people pills: prescriptions for happiness? The new generation of drugs that make you who you want to be. The Sunday Times Magazine (UK) (2003).
   Google Scholar
• WILLIAMS K: Embarrassing claim by psychiatrists. The West Australian, Thursday May 4 (2000) p15.
   Google Scholar
• DEWAR KM, STRAVYNSKI A: The quest for biological correlates of social phobia: an interim assessment. Acta Psychiatr. Scand. (2001) 103(4):244–251.
   PubMedGoogle Scholar
• ARGYROPOULOS SV, HOOD SD, NUTT DJ: Social phobia: illness or illusion? Acta Psychiatr. Scand. (2001) 103(4):241–243.
   Google Scholar
• LIEBOWITZ MR: Social phobia. Mod. Pro& Pharmacopsychiatry (1987) 22:141–173.
   PubMedGoogle Scholar
• CONNOR KM, DAVIDSON JR, CHURCHILL LE, SHERWOOD A, FOA E, WEISLER RH: Psychometric properties of the Social Phobia Inventory (SPIN). Br. J. Psychiatry (2000) 176:379–386.
   PubMed Web of Science ®Google Scholar
• ARGYROPOULOS SV, ADROVER M, HOOD SD et al.: Tryptophan depletion in treated social anxiety disorder: effects of autobiographical scripts and stressful speaking tasks. Psychopharmacology (2002) 16(3):A51.
   Google Scholar
• ARGYROPOULOS SV, BELL CJ, NUTT DJ: Brain function in social anxiety disorder. Psychiam. Gin. North Am. (2001) 24(4):707–722.
   PubMedGoogle Scholar
• SCHNEIER FR, LIEBOWITZ MR, ABI-DARGHAM A, ZEA-PONCE Y, LIN SH, LARUELLE M: Low dopamine D(2) receptor binding potential in social phobia. Am. J. Psychiatry (2000) 157(3)457–459.
   Google Scholar
• TIIHONENJ, KUIKKAJ, BERGSTROM K, LEPOLA U, KOPONEN H, LEINONEN E: Dopamine reuptake site densities in patients with social phobia. Am. J. Psychiatry (1997) 154(2):239–242.
   PubMedGoogle Scholar
• WALSH K, BENNETT G: Parkinson's disease and anxiety. Postgrad. Med. J. (2001) 77(904):89–93.
   PubMed Web of Science ®Google Scholar
• ROWE DC, STEVER C, GARD JM et al.: The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav. Genet. (1998) 28(3):215–225.
   PubMed Web of Science ®Google Scholar
• KENNEDY JL, NEVES-PEREIRA M, KING N et al.: Dopamine system genes not linked to social phobia. Psych/am Genet. (2001) 11(4):213–217.
   PubMedGoogle Scholar
• HIMLE JA, ABELSON JL, HAGHIGHTGOU H, HILL EM, NESSE RM, CURTIS GC: Effect of alcohol on social phobic anxiety. Am. Psychiatry (1999) 156(8):1237–1243.
   PubMedGoogle Scholar
• SIMPSON HB, SCHNEIER FR, CAMPEAS RB et al.: Imipramine in the treatment of social phobia. Clin. Psychopharmacol (1998) 18(2):132–135.
   PubMed Web of Science ®Google Scholar
• HOOD SD, NUTT DJ: Psychopharmacological treatments - an overview. In: International Handbook of Sodal Anxiety: Research, and Interventions relating to the Self and Shyness. Crozier WR, Alden LE (Eds), John Wiley & Sons Ltd, London (2001) 471–504.
   Google Scholar
• PANDE AC, DAVIDSON JRT, JEFFERSON JW et al.: Treatment of social phobia with gabapentin: a placebo-controlled study.' Clin. Psychopharmacol (1999) 19(0341–348.
   PubMedGoogle Scholar
• FELTNER DE, PANDE AC, POLLACK MH: A placebo-controlled study of pregabalin treatment of social phobia. 20th National Confrence of the Anxieh Disorders Association of America, Washington DC, USA NR–59.
   Google Scholar
• HOOD SD, NUTT DJ: Panic disorder. CNS (2000) 2(4):7–10. lor BELL C, ABRAMS J, NUTT D: Tiyptophan depletion and its implications for psychiatry. Br. J. Psychiatry (2001) 178:399–405.
   Google Scholar
• BELL C, FORSHALL S, ADROVER M et al.: Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. .1. Psychopharmacology (2002) 16(1):5–14.
   Google Scholar
• NUTT DJ, GLUE P, LAWSON C, WILSON S: Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch. Gen. Psychiatry(1990) 47(10):917–925.
   Google Scholar
• TILLFORS M, FURMARK T, MARTEINSDOTTIR I et al: Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am. J. Psychiatry (2001) 158(8):1220–1226.
   PubMedGoogle Scholar
• SARGENT PA, KJAER KH, BENCH CJ et al.: Brain serotoniniA receptor binding measured by positron emission tomography with [11C]-WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry(2000) 57(2):174–180.
   PubMedGoogle Scholar
• NUTT DJ: 5-HT in human anxiety disorders. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) WAM2–4.
   Google Scholar
• GROSS C, ZHUANG X, STARK K et al: SerotoniniA receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature (2002) 416(6879):396–400.
   PubMedGoogle Scholar
• ••An exquisite collection of research thatpresents a developmental aspect to serotonin activity in anxiety.
   Google Scholar
• GROSS C, SANTARELLI L, BRUNNER D, ZHUANG X, HEN R: Altered fear circuits in 5-HT(1A) receptor KO mice. Biol. Psychiatry (2000) 48(12):1157–1163. los. NUTT D, BALLENGER JC: Anxiety disorders: current needs and future prospects. In: Anxiety Disorders. Nutt D, Ballenger JC (Eds), Blackwell, Cambridge (2003) 501–510.
   Google Scholar
• CRESTANI F, LOREZ M, BAER K et al: Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat. Neurosci. (1999) 2(9):833–839.
   PubMed Web of Science ®Google Scholar
• RUDOLPH U, CRESTANI F, MOHLER H: GABAA receptor subtypes: dissecting their pharmacological functions. TIPS (2001) 22(4):188–194.
   PubMed Web of Science ®Google Scholar
• LOW K, CRESTANI F, KEIST R et al.: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290(5489):131–134.
   PubMedGoogle Scholar
• CRESTANI F, MARTIN JR, MOHLER H, RUDOLPH U: Mechanism of action of the hypnotic zolpidem in vivo. Br. j Pharmacol (2000) 131(7):1251–1254.
   PubMedGoogle Scholar
• MOHLER H, CRESTANI F, FRITSCHY JM, RUDOLPH U: Diversity of gabaergic inhibition: dissection by point mutations. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) THPM2–1.
   Google Scholar
• MCKERNAN RM, ROSAHL TW, REYNOLDS DS et al.: Sedative but not amdolytic properties of benzodiazepines are mediated by the GABA(A) receptor at subtype. Nat. Neurosci. (2000) 3(6):587–592.
   PubMed Web of Science ®Google Scholar
• ••The demonstration of differentialbenzodiazepine effects has opened the door for the development of more targeted therapies.
   Google Scholar
• ROWLETT JK: Therapeutic and side effects of benzodiazepines: GABAA subtype-mediated mechanisms in primates. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) THPM2–3.
   Google Scholar
• ATOR NA: Differential abuse liability profiles of GABA-A subtype selective compounds. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) THPM2–4.
   Google Scholar
• HOOD SD, NUTT DJ: Agents in development for anxiety disorders: current status and future potential. CNS Drugs (2000) 13(6):421–431.
   Google Scholar
• LINGFORD-HUGHES AR, UHL N, FEENEY AJ et al.: Is pagoclone a partial agonist at the central GABA-benzodiazepine receptor: a [11C]-flumazenil positron emission tomography study? Int. Neuropsychopharmacology (2000) 3:S288.
   Google Scholar
• SANDFORD JJ, FORSHALL S, BELL C et al.: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. Psychopharmacol (2001) 15(3):205–208.
   Google Scholar
• HAIG GM, DE WIT H, HUNT TL: Evaluation of the subjective and psychomotor effects of pagoclone, a partial GABAA agonist. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) W–33.
   Google Scholar
• ARGYROPOULOS S, NUTT D: Peptide receptors as targets for amdolytic drugs. In: Milestones M drug therapy - Anxiolytics. Briley M, Nutt D (Eds), Basel (2000) 151–175.
   Google Scholar
• •A comprehensive review of an important topic.
   Google Scholar
• HERNANDEZ-GOMEZ AM, AGUILAR-ROBLERO R, PEREZ DLM: Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids (2002) 23(1-3):283–290.
   PubMedGoogle Scholar
• TSUTSUMI T, AKIYOSHI J, HIKICHI T et al: Suppression of conditioned fear by administration of CCKB receptor antisense oligodeoxynucleotide into the lateral ventricle. Pharmacopsychiatry (2001) 34(6):232–237.
   PubMedGoogle Scholar
• VAN-MEGEN H-J, WESTENBERG H GM, DEN-BOER J-A, SLAAP B, SCHEEPMAKERS A: Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (1997) 129 (0357–364.
   PubMedGoogle Scholar
• SCHRUERS K, POLS H, OVERBEEK T, GRIEZ E: 10 g CCK-4 premedication and 35% CO2 challenge in healthy volunteers. Frog. Neuropsychopharmacol Biol. Psychiatry (2000) 24(3):409–418.
   PubMedGoogle Scholar
• KATZMAN MA, DUFFIN J, SHLIK J, BRAD WEJN J: The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers. Neuropsychopharmacology (2002) 26(6):824–831.
   PubMedGoogle Scholar
• MCDONALD IM: CCK2 receptor antagonists. Expert Opin. Titer. Patents (2001) 11(3):445–462.
   Web of Science ®Google Scholar
• GUTMAN DA, OWENS MJ, NEMEROFF CB: CRF receptor antagonists: a new approach to the treatment of depression. Pharmaceut. News (2001) 8:18–25.
   Google Scholar
• DAUTZENBERG FM, HAUGER RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci. (2002) 23(2):71–77.
   PubMed Web of Science ®Google Scholar
• •A thoughtful and well-constructed review of a difficult topic.
   Google Scholar
• MILLAN MJ, BROCCO M, GOBERT A, DOREY G, CASARA P, DEKEYNE A: Amdolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of amdolytic agent. Neuropsychopharmacology (2001) 25(4):585–600.
   PubMedGoogle Scholar
• GILLIGAN PJ, BALDAUF C, COCUZZA A et al.: The discovery of 4-(3-pentylamino)-2,7-dimethyl 8 (2 methy1-4-methoxypheny1)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg. Med. Chem. (2000) 8(1):181–189.
   PubMedGoogle Scholar
• MACIAG CM, DENT G, GILLIGAN P et al.: Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology (2002) 26(5):574–582.
   PubMedGoogle Scholar
• FERRARA G, SERRA M, ZAMMARETTI F et al.: Increased expression of the neuropeptide Y receptor Y(1) gene in the medial amygdala of transgenic mice induced by long-term treatment with progesterone or allopregnanolone. Neurochem. (2001) 79(2):417–425.
   PubMedGoogle Scholar
• MATHE A, HUSUM H, JIMINEZ P et al.: Neuropeptide Y is the marker for mood disorders and risk for alcohol dependence. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) W–60.
   Google Scholar
• BANNON AW, SEDA J, CARMOUCHE M et al.: Behavioral characterization of neuropeptide Y knockout mice. Brain Res. (2000) 868(1):79–87.
   PubMed Web of Science ®Google Scholar
• KASK A, HARRO J, VON HORSTEN S, REDROBE JP, DUMONT Y, QUIRION R: The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. (2002) 26(3):259–283.
   PubMed Web of Science ®Google Scholar
• THORSELL A, HEILIG M: Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides (2002) 36(2-3):182.
   PubMedGoogle Scholar
• SAJDYK TJ, SCHOBER DA, SMILEY DL, GEHLERT DR Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem. Pthav (2002) 71(3):419–423.
   PubMedGoogle Scholar
• ARGYROPOULOS S, NUTT D: Substance P antagonists: novel agents in the treatment of depression. Expert Opin. Invest. Drugs (2000) 9(8):1–5.
   Google Scholar
• MAUBACH KA, MARTIN K, CHICCHI G et al.: Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience (2002) 109(3):609–617.
   PubMedGoogle Scholar
• RIBEIRO RL, DE LIMA TC: Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice. Frog. Neuropsychopharmacol Biol. Psychiatry(2002) 26(5):861–869.
   PubMedGoogle Scholar
• GENTSCH C, CUTLER M, VASSOUT A, VEENSTRA S, BRUGGER F: Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav. Brain Res. (2002) 133(2):363–368.
   PubMedGoogle Scholar
• VARTY G, COHEN-WILLIAMS M, MORGAN C et al.: The gerbil elevated plus-maze II. Anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology (2002) 27(3):371.
   Google Scholar
• GRIEBEL G, PERRAULT G, SOUBRIE P: Effects of 5R48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology (lier) (2001) 158(3):241–251.
   PubMedGoogle Scholar
• RIBEIRO SJ, TEIXEIRA RM, CALIXTO JB, DE LIMA TC: Tachykinin NK(3)receptor involvement in anxiety. Neuropeptides (1999) 33(2): 181–188.
   PubMed Web of Science ®Google Scholar
• GIARDINA GAM, GRUGNI M, RAVEGLIA LF: Recent advances in neurokinin-3 receptor antagonists. Exp. Opin. Ther. Patents (2000) 10(6):939–960.
   Google Scholar
• WERSINGER SR, GINNS El, O'CARROLL A-M, LOLAIT SJ, YOUNG III WS: Vasopressin Vib receptor knockout reduces aggressive behavior in male mice. Ma Psychiatry(2002) 7:975–984.
   Google Scholar
• SERRADEIL-LE GAL C, WAGNON J, SIMIAND J et al.: Characterization of (2S,4/i) 1 [5 chloro-1- [(2,4-dimethoxyphenyflsulfony1]-3- (2-methoxy-phenyl) -2-0x0-2,3-dihydro-1H-indo1-3-y11-4-hydroxy-N,N-dimethy1-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin Vib receptor antagonist. J. Pharmacol Exp. The]: (2002) 300(3):1122–1130.
   PubMedGoogle Scholar
• GRIEBEL G, SIMIAND J, SERRADEIL-LE GAL C et al.: Amdolytic- and antidepressant-like effects of the non-peptide vasopressin Vib receptor antagonist, 55R149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA (2002) 99(9):6370–6375.
   Google Scholar
• ROSENBLUM LA, SMITH EL, ALTEMUS M et al: Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. Psychoneumendocrinology (2002) 27(6):651–660.
   PubMedGoogle Scholar
• BALE TL, DAVIS AM, AUGER AP, DORSA DM, MCCARTHY MM: CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J. Neurosci. (2001) 21(7):2546–2552.
   PubMed Web of Science ®Google Scholar
• ALTEMUS M, SWEDO SE, LEONARD HL et al.: Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch. Gen. Psychiatry (1994) 51(10):794–803.
   PubMedGoogle Scholar
• MOLLER C, SOMMER W, THORSELL A, HEILIG M: Amdogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology(1999)21(4):507–512.
   PubMedGoogle Scholar
• WRENN CC, CRAWLEY JN: Pharmacological evidence supporting a role for galanin in cognition and affect. l+og. Neuropsychopharmacol Biol. Pwchiaby (2001) 25(1):283–299.
   PubMedGoogle Scholar
• KHOSHBOUEI H, CECCHI M, DOVE S, JAVORS M, MORILAK DA: Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated amdolytic effect in central amygdala. Pharmacol Biochem. Behav. (2002) 71(3):407–417.
   PubMedGoogle Scholar
• KHOSHBOUEI H, CECCHI M, MORILAK DA: Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology (2002) 27(1):25–34.
   PubMedGoogle Scholar
• ADAMEC RE, BURTON P, SHALLOW T, BUDGELL J: Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in et al.: Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mG1u8) receptor. Neuropharmacology(2002) 43(2):251.
   Google Scholar
• SEGMAN RH, COOPER-KAZAZ R,180. MACCIARDI F et al.: Association between the dopamine transporter gene and posttraumatic stress disorder. MM. Psychiatry(2002) 7(8):903–907.
   Google Scholar
• FRISCH A, MICHAELOVSKY E, ROCKAH R et al: Association between181. obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Ear: Neuropsychopharmacol (2000)10(3):205–209.
   Google Scholar
• FALZONE TL, GELMAN DM, YOUNG JI, GRANDY DK, LOW MJ, RUBINSTEIN M: Absence of dopamine182. D4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. Eur.j Neurosci. (2002)15(1):158–164.
   Google Scholar
• DEGENHARDT L, HALL W: Cannabis and psychosis. Current Psychiatry Reports (2002) 4:191–196.
   PubMedGoogle Scholar
• SCHNEIER FR, LIEBOWITZ MR, ABI-DARGHAM A, ZEA-PONCE Y, LIN SH, LARUELLE M: Low dopamine D(2) receptor binding potential in social phobia.184.Am. .1 Psychiatry (2000) 157(3)457–459.
   Google Scholar
• ROBSON P: Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry (2001) 178:107–115.
   PubMed Web of Science ®Google Scholar
• •• anxiety-like behavior and unconditioned startle-effective hemisphere depends on the behavior. Physic] Behav. (1999) 65(4–5):739-751.
   Google Scholar
• ADAMEC RE, BURTON P, SHALLOW T, BUD GELL J: NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure-implications for anxiety associated with post-traumatic stress disorder. Physic] Behav. (1999) 65(4-5):723–737.
   PubMedGoogle Scholar
• NUTT DJ: The psychobiology of posttraumatic stress disorder. J. Psychiatry(2000) 5 (Supp1.61):24–29.
   Google Scholar
• MARTINEZ G, ROPERO C, FUNES A et al.: Effects of selective NMDA and non-NMDA blockade in the nucleus accumbens on the plus-maze test. Physic] Behav. (2002) 76(2):219–224.
   PubMedGoogle Scholar
• CHOJNACKA-WOJCIK E, KLODZINSKA A, PILC A: Glutamate receptor ligands as amdolytics. Can: Opin. Investig. Drugs(2001) 2(8):1112–1119.
   PubMedGoogle Scholar
• LEVINE LR, GAYDOS B, POTTER WZ, TOLLEFSON GD: The mG1u2/3 receptor agonist, LY354740, demonstrates anxiolytic activity in GAD. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) T–44.
   Google Scholar
• BRODKIN J, BUSSE C, SUKOFF SJ, VARNEY MA: Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with diazepam and buspirone. Pharmacol Biochem. Behav. (2002) 73(2):359–366.
   PubMedGoogle Scholar
• PILC A, KLODZINSKA A, BRANSKI P et al.: Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology(2002) 43(2):181–187.
   PubMed Web of Science ®Google Scholar
• PAGE ME, SZELIGA P, GASPARINI F, CRYAN JF: Neurochemical and behavioral assays support an anxiolytic-like profile for 2-methyl-6-(phenylethynyl) pyridine (MPEP), a metabotropic glutamate receptor 5 (mGluR5) antagonist. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) W44.
   Google Scholar
• VARNEY MA, ANDERSON J, BRISTOW L et al.: MTEP: a potent and highly selective metabotropic glutamate receptor subtype 5 (mGluR5) antagonist with anxiolytic activity. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) MP2–4.
   Google Scholar
• LINDEN A, JOHNSON B, PETERS S
   Google Scholar
• KATHURIA S, GAETANI S, FEGLEY D et al: Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. (2003) 9(1):76–81.
   PubMed Web of Science ®Google Scholar
• ••Describes an exciting avenue of futureanxiolytic research.
   Google Scholar
• STENFORS CM: 5-HT1A and 5-HT1g antagonists as new therapeutics agents. The American College of Neuropsychopharmacology: 42nd Annual Meeting, Puerto Rico (2002) WAM2–1.
   Google Scholar
• FIELD MJ, OLES RJ, SINGH L: Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br: J. Pharmacol (2001) 132(1):1–4.
   PubMed Web of Science ®Google Scholar
• HORVATH EJ, HORVATH K, HAMORI T, FEKETE MI, SOLYOM S, PALKOVITS M: Amdolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Frog. Neurobiol (2000) 60(4):309–342.
   Google Scholar
• LEWIS K, LI C, PERRIN MH et al: Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Arad Sci USA (2001) 98(13):7570–7575. CAAMANO CA, MORANO MI, AKIL H: Corticosteroid receptors: a dynamic interplay between protein folding and homeostatic control. Possible implications in psychiatric disorders. Psychopharmacol Bull. (2001) 35(1):6–23. DUKE-COHAN JS, GU J, MCLAUGHLIN DF, XUY, FREEMAN GJ, SCHLOSSMAN SF: Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proc. Natl. Acad. Sci. USA (1998) 95(19):11336–11341.
   Google Scholar
• SUEMARU K, ARAKI H, GOMITA Y: Involvement of neuronal nicotinic receptor in psychiatric disorders. Nippon Yakurigaku Zasshi (2002) 119(5)295–300.
   Google Scholar
• MULLEN G, NAPIER J, BALESTRA M et al.: (+Spiro [1 -azabicyclo [2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the a7 nicotinic acetylcholine receptor. J. Med. Chem. (2000) 43(22):4045–4050.
   Google Scholar
• RONZONI S, PERETTO I, GIARDINA GAM: Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists. Expert Opin. Ther. Patents (2001) 11(0525–546.
   Web of Science ®Google Scholar
• MCINTOSH JM, CORPUZ GO, LAYER RT et al: Isolation and characterisation of a novel conus peptide with apparent antinociceptive activity. BiolChem.(2000) 275(42):32391–32397.
   PubMedGoogle Scholar
• FEDOROVA I, HASHIMOTO A, FECIK RA et al.: Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol Exp. The]: (2001) 299(1):332–342. Patents Patents of special note have been highlighted as either of interest (8) or of considerable interest (88) to readers.
   Google Scholar